Article
The National Institutes of Health (NIH) National Cancer Institute has granted $124,000 to Aastrom Biosciences, Inc. to develop an immunotherapeutic treatment of malignant melanoma using AastromReplicell System cell production technology.
Daily Derm Times: March 24, 2025
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
“Open Sandwich” Moisturization Regimen Does Not Affect Bioactivity of Retinols and Retinoids
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
New Study Reveals Risk Factors for Persistent Urticaria
ESK-001: A Conversation with Jörn Drappa, MD, PhD, of Alumis on Breakthrough Data and the Future of Psoriasis Treatment